Navigation Links
Watson Presents Outlook for Continued Long Term Growth
Date:1/21/2011

r RAPAFLO® treatment for benign prostatic hyperplasia (BPH), GELNIQUE® treatment for overactive bladder (OAB), and ANDRODERM® and AndroGel® testosterone replacement therapies," said Wilkinson.  "We expanded our Womens Health franchise with the approval of ella®, our emergency contraceptive, the acquisition of Crinone® for the treatment of infertility, and the end-of-year approval of our novel oral contraceptive.  We also added a new product for the treatment of uterine fibroids to our development pipeline, and licensed and began development of our first biologic product."

"The most exciting milestone achieved during 2010 was the completion of the Phase III PREGNANT study of Prochieve® for the prevention of preterm birth," Wilkinson noted.  "Preterm birth represents a significant unmet medical need, and the clinical study data demonstrates a significant reduction in preterm birth at multiple time frames.  Results also indicated an improvement in infant outcomes.  We are preparing for the publication of the full clinical trials in the first quarter of 2011, and anticipate filing our New Drug Application (NDA) in the second quarter of 2011.  It is our goal to establish Prochieve® as the recommended treatment of choice for pregnant women with a short cervix."  

"We enter 2011 with an expanding womens health portfolio, a strong pipeline of products in the U.S., and we are implementing a strategy to expand our business into Canada, Latin America and Europe."

2010 Global Brands revenue is expected to be $400 million, and the Company expects 2011 Global Brands segment revenue of between $470 and $490 million, reflecting continued growth of its current promoted products, as well as the launch of new brand products into the U.S. market during the year.

Global OperationsRobert Stewart, Watson's Executive Vice President, Global Operations told analysts, "In 2010 we made tre
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
2. Watson Announces Preliminary Financial Performance for FY 2010
3. Watson to Host Investor Day on January 21 in New York City
4. Watsons Generic Fentora® Receives FDA Approval
5. Watson to Present at the 29th Annual JP Morgan Healthcare Conference
6. Watson Announces Novel Oral Contraceptive Approval
7. Watson and Richter Announce Exclusive License Agreement for Esmya™
8. Watson Confirms Exalgo™ Patent Challenge
9. Watson Announces Pricing of Secondary Offering By Selling Stockholder
10. Watson Announces Commencement of Secondary Offering by Selling Stockholder
11. Watson To Present At The 2010 Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... fourth quarter and full year ended December 31, 2014. ... PTC. We are now a growing commercial-stage biopharma company, ... rare disease space," stated Stuart W. Peltz, Ph.D., Chief ... bring the first treatment for Duchenne muscular dystrophy to ...
(Date:2/27/2015)... TEL-AVIV, Israel , February 27, 2015 ... Unternehmen baut sein bahnbrechendes Überwachungssystem für kongestive ... weiter aus -   ... Medical Technologies, die ein neuartiges Herzüberwachungssystem für ... gab heute bekannt, dass sie ein Finanzierungsvorhaben ...
(Date:2/27/2015)... -- Bionik Laboratories Corp. (OTC:DWTPD), a Delaware ... Bionik Laboratories, Inc., a Toronto ... accredited investors of units consisting of its common stock ... million. Shares of the Company,s common stock will continue ... symbol "DWTPD" until FINRA,s approval of the ticker "BNKL." ...
Breaking Medicine Technology:PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3
... SAN DIEGO, March 1, 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: ... present at the following investor conferences: Citi 2011 ... 10:00 a.m. Eastern Time at the Hilton New York Hotel ... Health Care Conference on Monday, March 7, 2011 at 4:45 ...
... March 1, 2011 Valeritas, Inc., ... and commercialization of innovative drug delivery solutions, announced ... has cleared the company,s V-Go Disposable Insulin Delivery ... the continuous subcutaneous delivery of insulin in preset ...
Cached Medicine Technology:Optimer Pharmaceuticals to Present at March 2011 Investor Conferences 2Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device for Use with NovoLog® 2Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device for Use with NovoLog® 3
(Date:2/27/2015)... 27, 2015 Mediaplanet today announces the ... a campaign that aims to bring blood health and ... conversation. The stories in this edition go beyond the ... clinical care, hard-hitting advocacy, research and technological strides needed ... the American Cancer Society, approximately every 3 minutes ...
(Date:2/27/2015)... TN (PRWEB) February 27, 2015 The ... Health, has announced a scholarship for rising freshmen undergraduate ... Nashville’s leading periodontist office specializing in many periodontal procedures ... and treatment of gum disease . In honor ... $1,000 college scholarship for eligible rising freshmen undergraduate students. ...
(Date:2/27/2015)... 27, 2015 Insight Accelerator Labs ... advance the development of an in-line urine flow ... is being developed in direct response to current ... accuracy and error margins with potentially grave consequences. ... measurement and provide trending data analysis to signal ...
(Date:2/27/2015)... Mirena IUD lawsuits ( http://www.mirenalawsuit2014.com/ ) ... uterine perforations and other serious harm due to spontaneous ... forward in the multicounty litigation underway in New Jersey’s ... Court records indicate that the proceeding’s 34th Case Management ... convened that same day. (In Re: Mirena Litigation; Case ...
(Date:2/27/2015)... Over 440,000 patients die annually as a ... two jumbo jet airplanes crashing each day. Now more than ... an effort to do all they can to stay safe. ... the 17th U.S. Surgeon General, discusses the importance of safer ... to address safety issues to ensure that all our patients ...
Breaking Medicine News(10 mins):Health News:Know Your Blood: Raising Awareness through Mediaplanet’s “Blood Health” Campaign 2Health News:Nashville Periodontist Office AIOH Announces 2015 Scholarship 2Health News:Output Medical Joins Insight Accelerator Labs 2Health News:Output Medical Joins Insight Accelerator Labs 3Health News:Mirena Lawsuits Progress in New Jersey with Issuance of New Case Management Order, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Progress in New Jersey with Issuance of New Case Management Order, Bernstein Liebhard LLP Reports 3Health News:Dr. Richard Carmona, the 17th U.S. Surgeon General, and IntelliCentrics Raise Awareness in Mediaplanet’s “Patient Safety” Campaign 2
... News) -- Average annual premiums for employer-sponsored family health coverage ... than $15,000, according to new research from the Kaiser Family ... average, U.S. workers now pay more than $4,000 each year ... in workers, wages, the 2011 employer health benefits survey found. ...
... The Austen BioInnovation Institute in Akron (ABIA), its founding members ... $500,000 award to fund the Accountable Care Community (ACC) initiative, ... today. ACC is a collective effort aiming to create ... the Akron region. The funding is part of ...
... research suggests that the modern day-day-night-night shift pattern for ... potentially carcinogenic as older, more extreme shift patterns. ... risk of cancer, although the biological mechanism responsible for ... paper,s lead author and a doctoral student in the ...
... Brinster of the University of Pennsylvania School of Veterinary ... according to an announcement today from the White House. ... United States government on scientists and engineers. Brinster, ... Penn Vet, is the first veterinarian and the seventh ...
... (HealthDay News) -- Older, overweight women have about the same ... when their leg strength and power was assessed relative to ... of normal weight, a new study has found. The ... likely to become disabled due to the loss of muscle ...
... Mozes HealthDay Reporter , MONDAY, Sept. 26 (HealthDay ... face a higher risk of dying from heart disease than ... findings also showed a slightly increased risk of cardiovascular trouble ... that the results may indicate a link between infertility and ...
Cached Medicine News:Health News:Cost of U.S. Workers' Health Premiums Surged in 2011 2Health News:Cost of U.S. Workers' Health Premiums Surged in 2011 3Health News:Austen BioInnovation Institute's Accountable Care Community initiative gains national support 2Health News:Modern shift work pattern potentially less harmful to health 2Health News:Penn veterinarian Ralph Brinster awarded National Medal of Science 2Health News:Extra Pounds Linked to Weaker Legs in Older Women 2Health News:Childless Men May Face Higher Heart Disease Risk 2Health News:Childless Men May Face Higher Heart Disease Risk 3
... CMC joint is the most common site for ... the CMC joint without restricting the wrist or ... persons who need to control or reduce subluxation ... perform work and leisure activities without pain. Also ...
... This is an excellent choice to treat ... MCP joint, basal joint arthritis, advanced carpal ... the thumb and wrist. Distal palmar ... flexion and full finger dexterity. Constructed ...
... CTi Wrist OTS is an off-the-shelf wrist orthotic designed ... of 3 pre-set ranges-of-motion (20°,35° and 50°). , ... sprains with TFCC tear-triangular fibrocartilage complex , ... nonunion , Partial tendon rupture , ...
... CTi Wrist Static is a solid, one-piece custom wrist ... stable, neutral position. , ,Indications: , Wrist ... fibrocartilage complex , Coles fracture - distal ... Partial tendon rupture , ORIF - Open ...
Medicine Products: